Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome
- 31 October 2002
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 39 (4) , 20-24
- https://doi.org/10.1053/shem.2002.36925
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- RASand Leukemia: From Basic Mechanisms to Gene-Directed TherapyJournal of Clinical Oncology, 1999
- Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signallingBiochemical Journal, 1996
- Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family.Proceedings of the National Academy of Sciences, 1995
- Protein Lipidation in Cell SignalingScience, 1995
- Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.The Journal of Experimental Medicine, 1995
- Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.The Journal of Experimental Medicine, 1994
- Ras regulatory interactions: Novel targets for anti‐cancer intervention?BioEssays, 1994
- RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemiaBlood, 1990
- The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencingBlood, 1990
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesPublished by Elsevier ,1988